BioElectronics and B. Braun Medical Ltd Apply for Prescription Payment Clearance on the UK Drug Tariff
FREDERICK, MD. Feb 18, 2016 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices, announced today that B. Braun has initiated the application for a listing of RecoveryRx® on the National Health Service (NHS) drug tariff (http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx). The UK drug tariff list establishes payment for prescription costs in the UK.
“Orthopedic surgeons who are using RecoveryRx see a significant clinical benefit,” commented Phil Cleary, Senior Product Group Manager, B. Braun Medical Ltd. “Obtaining a listing on the drug tariff will facilitate greater inclusion of RecoveryRx in all aspects of postoperative and rehabilitation care in orthopedics.”
BioElectronics Corporation Letter from the President 2/28/2017
2. Obtain reimbursement clearance from the National Health System in the UK and Canada. Recently we received a request for additional information on the cost benefit of ActiPatch from the NHS in the UK.
BioElectronics Corporation Announces Health Economics Study
FREDERICK, MD--(Marketwired - June 29, 2017) - BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce the completion of a health economics study using its nonprescription drug-free ActiPatch® Musculoskeletal Pain Therapy for chronic pain. The goal was to investigate how using ActiPatch as a pain therapy would affect overall healthcare costs in the UK.
The study involved thirty subjects and compared overall healthcare costs (drugs, physician visits etc.) between a baseline 3-month period and 3 months of using ActiPatch® therapy. In summary, subjects reported a:
53% reduction in primary care appointments 42% reduction in pain specialist appointments 75% reduction in physiotherapy appointments 37% reduction in prescription analgesic use
In addition to a significant reduction in pain and improvement in quality of life, ActiPatch use was found to result in a 42% net direct savings in healthcare costs.
ActiPatch® Musculoskeletal Pain Therapy is based on the newest understanding of chronic pain: chronic pain often results because nerves "learn" pain, a process known as central sensitization. ActiPatch is a wearable medical device that regulates nerve activity (neuromodulation) 24/7. This results in reduced nerve hyperactivity and provides effective pain relief. The drug-free devices are available on Amazon for $29.95 (720-hours) of on/off therapy or $9.95 for the 7-Day Trial device.
"This study provides strong economic and marketability evidence that when ActiPatch® is used as an active therapy for chronic pain, not only does it reduce chronic pain but it also significantly reduces the overall healthcare costs associated with managing chronic pain," stated Ian Rawe, Ph.D., Director of Clinical Research at BioElectronics.
BioElectronics' : President Discusses Company's Many Opportunities 08/22/2017
ActiPatch Cost Study Ian Rawe Ph. D. Cost basis of pain management 3 months before and 3 months with ActiPatch 30 Results submitted to NHS
Publishing the results of a health economics study, which indicated that using ActiPatch for chronic pain reduces total healthcare costs (medication and cost of services) by 42%.
Solicit Health Maintenance Organizations (HMO's) and other third party payers to use ActiPatch using the UK National Health System economic cost analysis of a 42% reduction in costs.
News 
Market Data 
Discover 
